KROS EBITDA Growth
Keros Therapeutics Inc · EBITDA Growth
KROS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-289.86%period ending
KROS TTM EBITDA YoY % (-419.15% → -289.86%)
Year-over-year change
High-resolution chart · PNG
KROS ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -289.8553% | |
| -376.4134% | |
| 155.0834% | |
| 149.2385% | |
| 126.6481% | |
| 120.1428% | |
| -11.4308% | |
| -27.2649% | |
| -32.6297% | |
| -37.9064% | |
| -46.3184% | |
| -78.8921% | |
| -65.4774% | |
| -78.7057% | |
| -84.5613% | |
| -27.5859% | |
| -41.3253% | |
| -31.9688% | |
| -24.5376% | |
| -77.3853% | |
| -102.8404% | |
| -171.0098% | |
| -419.1487% |